• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结直肠癌根治性切除术后随访中复发的早期预警:CA19-9 应纳入监测方案。

First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs.

机构信息

Department of Surgery, Saitama Medical Center, Jichi Medical University, Japan.

出版信息

Clin Colorectal Cancer. 2010 Jan;9(1):48-51. doi: 10.3816/CCC.2010.n.006.

DOI:10.3816/CCC.2010.n.006
PMID:20100688
Abstract

BACKGROUND

The aim of this study was to evaluate the contribution of each examination included in the postoperative surveillance program, especially that of serum tumor markers.

PATIENTS AND METHODS

Patients who underwent curative surgery for colorectal carcinoma (CRC) from January 2000 to December 2006 were enrolled. The postoperative surveillance program in our department includes tumor marker (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA] 19-9) measurement every 3 months for 5 years, chest radiograph or chest computed tomography (CT) every 3 months for 2 years and then every 6 months until 5 years, and abdominal CT every 3 months for 2 years and then every 6 months until 5 years. The first examination that revealed abnormality in patients who developed recurrence was analyzed.

RESULTS

During the study period, 105 recurrences were diagnosed. There were 45 hepatic recurrences, 23 local recurrences, 20 pulmonary recurrences, 16 lymph node recurrences, and 10 peritoneal recurrences. Computed tomography, CEA, and CA 19-9 were the first abnormal examination(s) in 77, 23, and 26 patients, respectively. Tumor markers detected the recurrence earlier than did CT in 27% of patients. CEA and CA 19-9 equally contributed to detection with respect to the number of patients, while the sites of detected recurrences differed.

CONCLUSION

For early detection of occult recurrence of CRC, CT was the most reliable modality. On the other hand, tumor markers were also relevant. Given the recent advances in multimodal approaches for advanced CRC, the combination of CT, CEA, and CA 19-9, which is currently not included in guidelines, should be routinely performed.

摘要

背景

本研究旨在评估术后监测方案中每项检查的贡献,尤其是血清肿瘤标志物的贡献。

患者和方法

我们纳入了 2000 年 1 月至 2006 年 12 月期间接受结直肠癌(CRC)根治性手术的患者。我们科室的术后监测方案包括每隔 3 个月检测肿瘤标志物(癌胚抗原[CEA]和糖链抗原[CA]19-9),连续 5 年;每隔 3 个月进行胸部 X 线或胸部计算机断层扫描(CT),连续 2 年,然后每 6 个月至 5 年;每隔 3 个月进行腹部 CT,连续 2 年,然后每 6 个月至 5 年。对出现复发的患者中首次发现异常的检查进行了分析。

结果

在研究期间,诊断出 105 例复发。其中 45 例肝转移,23 例局部复发,20 例肺转移,16 例淋巴结转移,10 例腹膜转移。CT、CEA 和 CA 19-9 分别在 77、23 和 26 例患者中首次发现异常。在 27%的患者中,肿瘤标志物比 CT 更早检测到复发。CEA 和 CA 19-9 在检测到的患者数量上具有同等的作用,但检测到的复发部位不同。

结论

对于 CRC 隐匿性复发的早期检测,CT 是最可靠的方法。另一方面,肿瘤标志物也很重要。鉴于目前对晚期 CRC 采用的多模态方法的进展,应常规进行目前未包含在指南中的 CT、CEA 和 CA 19-9 联合检测。

相似文献

1
First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs.结直肠癌根治性切除术后随访中复发的早期预警:CA19-9 应纳入监测方案。
Clin Colorectal Cancer. 2010 Jan;9(1):48-51. doi: 10.3816/CCC.2010.n.006.
2
CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.癌胚抗原(CEA)、组织多肽特异性抗原(TPS)、糖类抗原19-9(CA 19-9)、糖类抗原72-4(CA 72-4)及粪便潜血试验在结直肠癌手术切除术前诊断及随访中的应用
Anticancer Res. 1999 Jul-Aug;19(4A):2443-50.
3
Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin.对接受细胞减灭术和化疗治疗的结直肠源性腹膜癌患者的随访。
Eur J Surg Oncol. 2004 Apr;30(3):280-5. doi: 10.1016/j.ejso.2003.12.003.
4
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.癌胚抗原(CEA)、组织多肽抗原(TPA)、金标免疫渗滤法(GICA)、糖类抗原72.4(CA 72.4)及糖类抗原195(CA 195)在原发性结直肠癌诊断及其复发诊断中的应用价值
Cancer Detect Prev. 1995;19(2):183-95.
5
Serum carcinoembryonic antigen levels in patients operated for colorectal carcinoma.接受结直肠癌手术患者的血清癌胚抗原水平
Wien Klin Wochenschr. 2001;113 Suppl 3:32-8.
6
Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified?UICC I期结直肠癌术后复发的监测:癌胚抗原随访是否合理?
Hepatogastroenterology. 2005 Mar-Apr;52(62):444-9.
7
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.常规血清癌胚抗原检测及计算机断层扫描在结直肠癌辅助化疗后患者监测中的价值
J Clin Oncol. 2004 Apr 15;22(8):1420-9. doi: 10.1200/JCO.2004.05.041. Epub 2004 Mar 8.
8
[The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].[结直肠癌免疫指标及肿瘤标志物的术前和术后监测]
Khirurgiia (Sofiia). 1998;51(3):42-8.
9
Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.多种分子标志物对接受根治性切除的II期结直肠癌患者的预后意义。
Ann Surg. 2007 Dec;246(6):1040-6. doi: 10.1097/SLA.0b013e318142d918.
10
[Patient compliance and efficacy of diagnostic procedures in the surveillance of colorectal cancer: experience from a cancer center].[结直肠癌监测中诊断程序的患者依从性及疗效:来自某癌症中心的经验]
Z Gastroenterol. 2005 Apr;43(4):357-65. doi: 10.1055/s-2004-813814.

引用本文的文献

1
MicroRNA-193a-3p as a Valuable Biomarker for Discriminating between Colorectal Cancer and Colorectal Adenoma Patients.miR-193a-3p 作为一种有价值的生物标志物,可用于区分结直肠癌和结直肠腺瘤患者。
Int J Mol Sci. 2024 Jul 26;25(15):8156. doi: 10.3390/ijms25158156.
2
Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer.结直肠癌患者辅助化疗期间血清 CEA、CA19-9、CRP、YKL-40 和 IL-6 的一过性变化与生存关系
Int J Mol Sci. 2023 Apr 4;24(7):6753. doi: 10.3390/ijms24076753.
3
Prognostic Value of Preoperative Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Levels for Adjuvant Chemotherapy in Stage II Colorectal Cancer: A Nationwide Multicenter Retrospective Study.
术前癌胚抗原和糖类抗原19-9水平对Ⅱ期结直肠癌辅助化疗的预后价值:一项全国多中心回顾性研究
J Anus Rectum Colon. 2022 Oct 27;6(4):249-258. doi: 10.23922/jarc.2022-020. eCollection 2022.
4
P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).P.R.O.P.S. - 一种新型的术前预测评分,用于评估考虑进行细胞减灭术 (CRS) 和腹腔热灌注化疗 (HIPEC) 的结直肠腹膜转移患者的不可切除性。
World J Surg Oncol. 2019 Aug 7;17(1):138. doi: 10.1186/s12957-019-1673-x.
5
Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients.血浆微小RNA水平联合癌胚抗原和糖类抗原19-9在结直肠癌患者随访中的应用
Cancers (Basel). 2019 Jun 21;11(6):864. doi: 10.3390/cancers11060864.
6
Blood CEA levels for detecting recurrent colorectal cancer.用于检测复发性结直肠癌的血液癌胚抗原水平。
Cochrane Database Syst Rev. 2015 Dec 10;2015(12):CD011134. doi: 10.1002/14651858.CD011134.pub2.
7
Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.在一例转移性直肠腺癌中,癌胚抗原(CEA)而非糖类抗原19-9(CA 19-9)作为疾病活动血清生物标志物的相关性。
Cancer Biol Ther. 2015;16(8):1136-9. doi: 10.1080/15384047.2015.1057360.
8
Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.唾液糖缀合物在结直肠癌诊断和治疗中的临床病理应用价值
World J Gastroenterol. 2014 May 28;20(20):6123-32. doi: 10.3748/wjg.v20.i20.6123.